Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

Nursing --- Clinical & internal medicine --- Surgery --- Biology CAR-T --- Manufacturing CAR-T --- Indications CAR-T --- Complications CAR-T --- Access CAR-T --- Open Access --- Immunoteràpia --- Cèl·lules T

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Science: general issues --- Pharmacology --- immune checkpoint --- cancer therapy --- gene regulation --- acquired resistance --- CAR-T and CAR-NK cell-therapy --- immune checkpoint --- cancer therapy --- gene regulation --- acquired resistance --- CAR-T and CAR-NK cell-therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Modern cell biology has brought improvements in therapy for advanced malignant diseases through immunomodulation, hematopoietic stem cell transplantation, and other advanced techniques. Collected here are selected papers from the Fifth International Symposium of Keio University for Life Sciences and Medicine on Cell Therapy. All chapters include innovative basic research for clinical application: immunotherapy, cancer vaccination, molecular biology of hematopoietic stem cells, stem cell processing, and gene therapy. The book is divided into three parts: Immunotherapy for malignant diseases; Hematopoietic stem cell biology and clinical application; and International collaboration in hematopoietic stem cell transplantation. Included in the third part is information on bone marrow registries from around the world. The book thus presents up-to-date information on biological and clinical aspects of treatment, with insight into the future of cell therapy.

Hematopoietic Stem Cell Transplantation. --- Hematopoietic Stem Cells --- Immunotherapy, Adoptive. --- Neoplasms --- Cellular therapy --- Cell therapy --- Cells --- Therapy, Cellular --- Organotherapy --- Therapeutics, Physiological --- Transplantation of organs, tissues, etc. --- Cell transplantation --- Adoptive Immunotherapy --- Cellular Immunotherapy, Adoptive --- Immunotherapy, Adoptive Cellular --- Adoptive Cellular Immunotherapy --- Adoptive Cellular Immunotherapies --- Adoptive Immunotherapies --- Cellular Immunotherapies, Adoptive --- Immunotherapies, Adoptive --- Immunotherapies, Adoptive Cellular --- Killer Cells, Lymphokine-Activated --- Cytapheresis --- Lymphocytes, Tumor-Infiltrating --- Monocytes, Activated Killer --- Transplantation, Hematopoietic Stem Cell --- Stem Cell Transplantation, Hematopoietic --- Bone Marrow Transplantation --- Bone Marrow Purging --- Hematopoietic Stem Cell Mobilization --- physiology. --- therapy. --- Therapeutic use --- transplantation --- Hematopoietic Stem Cell Transplantation --- Immunotherapy, Adoptive --- physiology --- therapy --- Physiology --- Therapy --- CAR T-Cell Therapy --- Chimeric Antigen Receptor Therapy --- CAR T Cell Therapy --- CAR T-Cell Therapies --- T-Cell Therapies, CAR --- T-Cell Therapy, CAR --- Therapies, CAR T-Cell --- Therapy, CAR T-Cell --- Receptors, Chimeric Antigen --- Cell biology. --- Molecular biology. --- Oncology  . --- Cell Biology. --- Molecular Medicine. --- Oncology. --- Tumors --- Molecular biochemistry --- Molecular biophysics --- Biochemistry --- Biophysics --- Biomolecules --- Systems biology --- Cell biology --- Cellular biology --- Biology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Hematopoietic stem cells --- Cellular therapy --- Hematopoietic stem cell disorders --- Cellular therapy. --- Hematopoietic Stem Cell Transplantation. --- Immunotherapy, Adoptive. --- Transplantation --- Treatment. --- Transplantation. --- Adoptive Immunotherapy --- CAR T-Cell Therapy --- Cellular Immunotherapy, Adoptive --- Chimeric Antigen Receptor Therapy --- Immunotherapy, Adoptive Cellular --- Adoptive Cellular Immunotherapy --- Adoptive Cellular Immunotherapies --- Adoptive Immunotherapies --- CAR T Cell Therapy --- CAR T-Cell Therapies --- Cellular Immunotherapies, Adoptive --- Immunotherapies, Adoptive --- Immunotherapies, Adoptive Cellular --- T-Cell Therapies, CAR --- T-Cell Therapy, CAR --- Therapies, CAR T-Cell --- Therapy, CAR T-Cell --- Receptors, Chimeric Antigen --- Killer Cells, Lymphokine-Activated --- Cytapheresis --- Lymphocytes, Tumor-Infiltrating --- Monocytes, Activated Killer --- Transplantation, Hematopoietic Stem Cell --- Stem Cell Transplantation, Hematopoietic --- Hematopoietic Stem Cells --- Bone Marrow Transplantation --- Bone Marrow Purging --- Hematopoietic Stem Cell Mobilization --- HSCs (Hematopoietic stem cells) --- Blood cells --- Bone marrow cells --- Hematopoietic system --- Multipotent stem cells --- Cell therapy --- Cells --- Therapy, Cellular --- Organotherapy --- Therapeutics, Physiological --- Transplantation of organs, tissues, etc. --- Cell transplantation --- Hematopoietic stem cell diseases --- Blood --- transplantation --- Therapeutic use --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate